30 June 2020
Blytheweigh is appointed by Brains Bioceuticals and Hummingbird Resources
During an unprecedented second quarter to 2020, Blytheweigh (“Bw”) was pleased to be appointed by Brains Bioceuticals and Hummingbird Resources.
Brains Bioceuticals is one of only nine companies in the world with an API designation for CBD under EU-GMPD1 and one of only three EU CBD companies with a licence to manufacture an API from a natural source. The Company commercialises its CBD API by supplying the ingredient to the pharmaceutical, veterinary, wellness, and sports industries, as well as producing its own Brains labelled products.
Hummingbird Resources is an AIM-listed gold producer, developer and explorer. The Company has two core gold projects, the Yanfolila Gold Mine in Mali, which is expected to produce 110,000-125,000 ounces of gold in 2020, and the recently acquired Kouroussa Gold Project in Guinea, which has a resource of over one million ounces averaging 3.08 grammes per tonne. Hummingbird also has a controlling interest in the Dugbe Gold Project that is being developed by ARX Resources through an earn-in agreement.
Tim Blythe, Bw Partner, said:
“We are delighted to welcome Brains and Hummingbird into our portfolio. Both companies have exciting stories where sustainability is at the core of each business and we look forward to working with the respective teams to develop their communications strategies.”
Tim Blythe, Camilla Horsfall or Megan Ray on 020 7138 3204